BAALC-AS2: A Potential Drug Target and Biomarker (G157556)

Target Name: BAALC-AS2

NCBI ID: G157556

BAALC-AS2

Other Name(s): C8orf56 | BAALC antisense RNA 2 | BAALCOS

BAALC-AS2: A Potential Drug Target and Biomarker

Introduction

BAALC-AS2 (Bialleucel-associated compactin-2) is a protein that is expressed in various tissues of the human body, including the brain, pancreas, and gastrointestinal tract. It has been identified as a potential drug target and biomarker for various diseases , including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will discuss the biology and potential therapeutic applications of BAALC-AS2.

History of the Discovery

BAALC-AS2 was first identified in the late 1990s by researchers at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in the United States. They found that BAALC-AS2 was expressed in the pancreas and was associated with insulin secretion. Since Then, studies have continued to investigate the functions of BAALC-AS2 and its potential as a drug target.

Potential Drug Target

BAALC-AS2 has been shown to play a role in various cellular processes that are important for disease progression, including inflammation, fibrosis, and autophagy. It is also involved in the regulation of cellular signaling pathways that are involved in cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising aspects of BAALC-AS2 as a drug target is its potential to intervene in the regulation of pancreatic cancer. Studies have shown that BAALC-AS2 is overexpressed in pancreatic cancer and that inhibition of its activity can lead to a reduction in tumor growth. Additionally, BAALC-AS2 has been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels form in response to cancer growth.

Potential Biomarkers

BAALC-AS2 has also been identified as a potential biomarker for various diseases, including pancreatic cancer, neurodegenerative diseases, and autoimmune disorders. The identification of BAALC-AS2 as a biomarker has the potential to improve diagnosis and treatment outcomes for these diseases.

One of the most promising applications of BAALC-AS2 as a biomarker is its potential to detect pancreatic cancer at an early stage. Studies have shown that BAALC-AS2 can be used as a diagnostic marker for pancreatic cancer, with higher levels of BAALC-AS2 in the serum indicating a greater risk of pancreatic cancer.

Another potential application of BAALC-AS2 as a biomarker is its ability to track the progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have shown that BAALC-AS2 is involved in the regulation of neurodegenerate diseases and that its activity can be used as a biomarker for disease progression.

Conclusion

BAALC-AS2 is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its functions have been shown to include the regulation of cellular signaling pathways, angiogenesis, and the regulation of disease progression. Further research is needed to fully understand the potential therapeutic applications of BAALC-AS2 and to develop safe and effective treatments for the various diseases associated with its presence.

Protein Name: BAALC Antisense RNA 2

The "BAALC-AS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BAALC-AS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets